RNAC Cartesian Therapeutics, Inc.

Price Chart

Executive Summary

Cartesian Therapeutics secured a senior secured credit facility from K2 HealthVentures for up to $150 million, with an initial $50 million tranche funded at closing. The non-dilutive financing extends cash runway into 2028 and funds clinical catalysts, including Phase 3 AURORA topline data in 1Q27. The CMO resigned for personal reasons, and the lender has the right to convert up to $15 million of principal into common stock at $8.2526 per share.

Key Financial Metrics

Actionable Insight

Key Facts

• Up to $150 million senior secured credit facility from K2 HealthVentures, with $50 million funded at closing on May 22, 2026.
• Second tranche of $25 million available Jan 1, 2027 – Dec 1, 2027, subject to positive Phase 3 AURORA data and raising $125M in financing (at least $75M equity).
• Third tranche of $25 million available Jan 1, 2028 – Jun 1, 2028, subject to FDA approval of Descartes-08 for gMG and first commercial sale.
• Fourth tranche of up to $50 million available at lender's sole discretion.
• Interest rate: greater of 8.95% or Prime + 2.20%, maturing June 1, 2030; amortization begins July 1, 2029.
• Lenders may convert up to $15 million of principal into common stock at $8.2526 per share (or lower in a qualified financing).
• Topline Phase 3 AURORA data for Descartes-08 in myasthenia gravis expected in 1Q27; BLA filing planned for mid-2027.
• CMO Milos Miljkovic resigned effective May 31, 2026; Head of R&D Peter Traber to support ongoing trials and BLA preparation.
• Cash runway extended into 2028, covering three clinical data readouts and pre-commercial activities.

Financial Impact

Up to $150 million in new debt financing; $50 million drawn immediately. Interest at 8.95% floor. Potential dilution from conversion of up to $15 million principal into equity at $8.2526/share.

Risk Factors

• Phase 3 AURORA trial may fail to meet primary endpoint, jeopardizing second tranche and BLA timeline.
• Conversion of up to $15M principal into equity could dilute existing shareholders if stock trades below $8.2526.
• Stringent financial covenants (minimum cash, net product revenue of $40M/quarter from 2029) could trigger default if commercial launch is delayed.
• CMO departure may cause temporary disruption, though Head of R&D is experienced.

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status